For US Healthcare Professionals Only
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
Dermira to transition development and commercialization responsibility for CIMZIA® (certolizumab pegol) in psoriasis back to UCB
Decision reflects both companies’ strategic priorities
UCB remains committed to bringing CIMZIA to psoriasis patients upon regulatory approval
New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2
Treatment with CIMZIA was associated with significant and clinically meaningful improvements in quality of life and work productivity3,4
No new safety signals were observed in the psoriasis trials and the safety profile remains consistent with CIMZIA’s other indications
Approval Announcement
U.S. Food and Drug Administration (FDA) approves label change for UCB’s CIMZIA® (certolizumab pegol)
Data added to the label includes first-of-their-kind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant1,2